Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

23.48USD
4:00pm EDT
Change (% chg)

$0.08 (+0.34%)
Prev Close
$23.40
Open
$23.36
Day's High
$23.49
Day's Low
$23.30
Volume
2,569,189
Avg. Vol
537,374
52-wk High
$23.54
52-wk Low
$2.86

Latest Key Developments (Source: Significant Developments)

Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
Thursday, 18 Oct 2018 01:10am EDT 

Oct 18 (Reuters) - Endocyte Inc ::ENDOCYTE ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $2.1 BILLION.NOVARTIS TO ACQUIRE ENDOCYTE FOR $24 PER FULLY DILUTED SHARE IN CASH.TRANSACTION WAS UNANIMOUSLY APPROVED BY THE BOARD OF DIRECTORS OF ENDOCYTE.THIS OFFER REPRESENTS A PREMIUM OF 54% PERCENT TO ENDOCYTE'S CLOSING PRICE OF $15.56 ON OCTOBER 17, 2018.UNTIL THAT TIME, ENDOCYTE WILL CONTINUE TO OPERATE AS A SEPARATE AND INDEPENDENT COMPANY.COMPLETION OF TRANSACTION IS EXPECTED IN FIRST HALF OF 2019.  Full Article

Endocyte Prices 9.46 Mln Common Stock Offering At $18.50 Per Share
Tuesday, 11 Sep 2018 07:52pm EDT 

Sept 11 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.46 MILLION COMMON SHARES PRICED AT $18.50PER SHARE.ALSO GRANTED UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 1.42 MILLION SHARES OF ITS COMMON STOCK ON SAME TERMS AND CONDITIONS.  Full Article

Endocyte Announces $175.0 Mln Proposed Public Offering Of Common Stock
Monday, 10 Sep 2018 04:15pm EDT 

Sept 10 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES $175.0 MILLION PROPOSED PUBLIC OFFERING OF COMMON STOCK.ENDOCYTE INC - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING TO FUND CONTINUED CLINICAL DEVELOPMENT OF ITS PIPELINE PRODUCTS.ENDOCYTE INC - INTENDS TO ALSO USE NET PROCEEDS FROM PROPOSED OFFERING TO FUND PREPARATION FOR COMMERCIAL LAUNCH OF (177)LU-PSMA-617, IF APPROVED.  Full Article

Endocyte Announces Closing Of Public Offering Of Common Stock
Friday, 2 Mar 2018 04:01pm EST 

March 2 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK.  Full Article

Endocyte Announces Pricing Of Public Offering Of Common Stock
Wednesday, 28 Feb 2018 09:17am EST 

Feb 28 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 17.9 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

Endocyte Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Feb 2018 08:01pm EST 

Feb 27 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.‍INTENDS TO OFFER AND SELL SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN REGISTERED PUBLIC OFFERING​.  Full Article

Endocyte And ITM Announce Supply Agreement
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Endocyte Inc ::ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL.ENDOCYTE INC - UNDER SUPPLY AGREEMENT, ITM TO SUPPLY TO CO, MEDICAL RADIOISOTOPE NO-CARRIER-ADDED LUTETIUM, ENDOLUCINBETA.ENDOCYTE INC - PHASE 3 VISION TRIAL EXPECTED TO BE INITIATED BY ENDOCYTE IN Q2 OF 2018.  Full Article

Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.ANNOUNCED AGREEMENT FOR CLINICAL SUPPLY OF NO-CARRIER-ADDED LUTETIUM WITH ITM.CAR T-CELL THERAPY EXPECTED TO BEGIN CLINICAL DEVELOPMENT IN Q4 OF 2018.‍ ENROLLMENT OF VISION TRIAL IS EXPECTED TO BEGIN IN Q2 OF 2018 AND IS EXPECTED TO BE COMPLETED IN 18-24 MONTHS​.CASH, CASH EQUIVALENTS & INVESTMENTS WERE $97.5 MILLION AT DEC. 31, 2017, VERSUS $103.1 MILLION AT SEPT. 30, 2017.‍ FIRST INTERIM ASSESSMENT OF OS FOR VISION TRIAL COULD OCCUR AS EARLY AS SECOND HALF OF 2019​.ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $50 MILLION.HAS SUFFICIENT CASH TO FUND ITS ACTIVITIES INTO SECOND HALF OF 2019 THROUGH MANY IMPORTANT MILESTONES.  Full Article

‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6
Thursday, 16 Nov 2017 04:52pm EST 

Nov 16 (Reuters) - Endocyte Inc :‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​.  Full Article

Endocyte Q3 loss per share $0.55
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Endocyte Inc :Endocyte reports third quarter financial results.Q3 loss per share $0.55.  Full Article

Deals of the day-Mergers and acquisitions

Oct 18 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: